ClinicalTrials.gg
CompletedNCT01645280Updated May 12, 2016Results posted

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

A Phase 2 interventional study of Placebo + methotrexate (MTX) (Group 1) and Ustekinumab + MTX (Group 2) in Arthritis, Rheumatoid, sponsored by Janssen Research & Development, LLC. Completed at 51 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-12.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
36th of 113
274 · median 130
Started
2012
with 10 others
Phase 2
10 of 113
2 open now
Registered
64th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 36th largest by enrollment, is one of 11 that started in 2012, is one of 10 in phase 2, and was the 64th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy and to evaluate the safety of ustekinumab and CNTO 1959 in this population.

Read the detailed description

This is a randomized (patients assigned to treatment by chance), double-blind (study personnel and patients will not know what treatment is being assigned to patients), multicenter, placebo-controlled (a placebo is a treatment identical in appearance to the study agent, but containing no active ingredient), dose-ranging study. Approximately 250 patients will be randomly assigned to 1 of 5 treatment groups. The maximum length of study participation is 54 weeks, including a 6-week screening period. The end of the study will be the last follow-up visit of the last patient. Study visits and evaluations will occur, and patient safety will be monitored throughout the study.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • Active rheumatoid arthritis
  • Ustekinumab
  • STELARA
  • CNTO 1959
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had RA for at least 6 months prior to screening
  • Have a diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association - Be positive for either anti-cyclic citrullinated peptide antibody or rheumatoid factor in serum at screening
  • Have been treated with and tolerated MTX for at least 6 months prior to screening, and have a MTX dose of >= 10 mg and \<= 25 mg per week and stable for at least 12 weeks prior to first administration of study agent
  • Have active RA, defined as persistent disease activity with both of the following criteria: at least 6 swollen and 6 tender joints at the time of screening and baseline; serum C-reactive protein (CRP) >= 0.80 mg/dL at screening. The investigator may consider the patient eligible if the CRP value is at least 0.80 mg/dL in a single repeat testing during the screening period
  • If using oral , must be on a stable dose of \<= 10 mg/day of prednisone or an equipotent dose of another oral corticosteroid for at least 2 weeks prior to the first administration of study agent. If not using corticosteroids at Week 0, the patient must not have received oral corticosteroids for at least 2 weeks prior to the first administration of study agent
  • If using nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesics regularly for RA, the patient must have been on a stable dose for at least 2 weeks prior to the first administration of study agent. If not using NSAIDs or other analgesics for RA at Week 0, the patient must have not received NSAIDs or other analgesics for RA for at least 2 weeks prior to the first administration of study agent

Exclusion criteria

Exclusion Criteria:

  • Has other inflammatory diseases, including but not limited to psoriatic arthritis, ankylosing spondylitis (AS), systemic lupus erythematosus, or Lyme disease, that might confound the evaluation of the benefit of study agent therapy
  • Has current signs or symptoms of liver insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive, or uncontrolled
  • Has any known or history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to the first administration of study agent)
  • Has a history of lymphoproliferative disease, including lymphoma, or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location, or splenomegaly
  • Has known allergies, , or intolerance to ustekinumab or CNTO 1959 or its inactive ingredients
  • Has ever received any approved or biologic agent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
274 participants (actual)

Study arms

  • Placebo comparator
    Group 1

    Drug: Placebo + methotrexate (MTX) (Group 1)

  • Experimental
    Group 2

    Drug: Ustekinumab + MTX (Group 2)

  • Experimental
    Group 3

    Drug: Ustekinumab + MTX (Group 3)

  • Experimental
    Group 4

    Drug: CNTO 1959 + MTX (Group 4)

  • Experimental
    Group 5

    Drug: CNTO 1959 + MTX (Group 5)

Interventions

  • DrugPlacebo + methotrexate (MTX) (Group 1)

    Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)

  • DrugUstekinumab + MTX (Group 2)

    Drug pages: Ustekinumab · Methotrexate

    Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)

  • DrugUstekinumab + MTX (Group 3)

    Drug pages: Ustekinumab · Methotrexate

    Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)

  • DrugCNTO 1959 + MTX (Group 4)

    Drug pages: Guselkumab · Methotrexate

    CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)

  • DrugCNTO 1959 + MTX (Group 5)

    Drug pages: Guselkumab · Methotrexate

    CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28

    The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) patient's assessment of arthritis pain-visual analog scale, 2) patient's global assessment of disease activity-visual analog scale, 3) physician's global assessment of disease activity-visual analog scale, 4) patient's assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-Di), 5) C-reactive protein (CRP).

    Time frame: Week 28

Secondary outcomes

  1. Change From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28

    The DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, CRP (mG/L) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

    Time frame: From Baseline to Week 28

  2. Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 12

    The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 2) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 3) Physician's Global Assessment of Disease Activity-Visual Analog Scale, 4) Patient's Assessment of Physical Function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI), 5) C-reactive Protein (CRP).

    Time frame: Week 12

  3. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28

    The Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline and Week 28

07

Results

Posted Dec 19, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 Weeks
Started5554555455
Completed4951494847
Not completed63668
Withdrew: Death01000
Withdrew: Withdrawal by subject40245
Withdrew: Lost to follow-up00021
Withdrew: Other11200
Withdrew: Treatment not completed/completed f/u11202

Outcome measures

PrimaryPercentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28

The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) patient's assessment of arthritis pain-visual analog scale, 2) patient's global assessment of disease activity-visual analog scale, 3) physician's global assessment of disease activity-visual analog scale, 4) patient's assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-Di), 5) C-reactive protein (CRP).

Time frame:
Week 28
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28
percentage of participantsPlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 Weeks
Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 2840.052.754.544.438.2
Statistical analysis
  • Placebo vs Ustekinumab 90 mg Every 8 Weeks · Cochran-Mantel-Haenszel · p = 0.184Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
  • Placebo vs Ustekinumab 90 mg Every 12 Weeks · Cochran-Mantel-Haenszel · p = 0.130Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
  • Placebo vs CNTO1959 200 mg Every 8 Weeks · Cochran-Mantel-Haenszel · p = 0.642Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
  • Placebo vs CNTO1959 50 mg Every 8 Weeks · Cochran-Mantel-Haenszel · p = 0.832Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
SecondaryChange From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28

The DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, CRP (mG/L) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

Time frame:
From Baseline to Week 28
Reported as:
Least squares mean · units on scale
Change From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28
units on scalePlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 Weeks
Change From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28-0.94 ± 0.174-1.52 ± 0.185-1.49 ± 0.183-1.21 ± 0.1706.07 ± 0.821
Statistical analysis
  • Placebo vs Ustekinumab 90 mg Every 8 Weeks · ANCOVA · p = 0.019Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.
  • Placebo vs Ustekinumab 90 mg Every 12 Weeks · ANCOVA · p = 0.025Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.
  • Placebo vs CNTO1959 200 mg Every 8 Weeks · ANCOVA · p = 0.248Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.
  • Placebo vs CNTO1959 50 mg Every 8 Weeks · ANCOVA · p = 0.045Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.
SecondaryPercentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 12

The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 2) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 3) Physician's Global Assessment of Disease Activity-Visual Analog Scale, 4) Patient's Assessment of Physical Function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI), 5) C-reactive Protein (CRP).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 12
percentage of participantsPlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 Weeks
Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 1229.137.034.533.320.0
Statistical analysis
  • Placebo vs Ustekinumab 90 mg Every 8 Weeks · Cochran-Mantel-Haenszel · p = 0.381Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
  • Placebo vs Ustekinumab 90 mg Every 12 Weeks · Cochran-Mantel-Haenszel · p = 0.543Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
  • Placebo vs CNTO1959 200 mg Every 8 Weeks · Cochran-Mantel-Haenszel · p = 0.629Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
  • Placebo vs CNTO1959 50 mg Every 8 Weeks · Cochran-Mantel-Haenszel · p = 0.273Screening CRP level (\>= 1.50 mg/dL; \< 1.50 mg/dL) was used as stratification factors.
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28

The Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline and Week 28
Reported as:
Least squares mean · units on scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28
units on scalePlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 Weeks
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28-0.30 ± 0.074-0.48 ± 0.072-0.44 ± 0.071-0.41 ± 0.075-0.39 ± 0.076
Statistical analysis
  • Placebo vs Ustekinumab 90 mg Every 8 Weeks · ANCOVA · p = 0.060Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.
  • Placebo vs Ustekinumab 90 mg Every 12 Weeks · ANCOVA · p = 0.134Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.
  • Placebo vs CNTO1959 200 mg Every 8 Weeks · ANCOVA · p = 0.280Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.
  • Placebo vs CNTO1959 50 mg Every 8 Weeks · ANCOVA · p = 0.345Treatment, screening CRP level (\>=1.50 mg/dL, \<1.50mg/dL) and baseline score as covariates.

Adverse events

Collected over Week 0 to 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/55 (5.5%)13/55 (23.6%)
Placebo (Early Escape)—1/16 (6.3%)6/16 (37.5%)
Ustekinumab 90 mg Every 8 Weeks—4/54 (7.4%)15/54 (27.8%)
Ustekinumab 90 mg Every 12 Weeks—3/55 (5.5%)15/55 (27.3%)
CNTO1959 200 mg Every 8 Weeks—3/54 (5.6%)18/54 (33.3%)
CNTO1959 50 mg Every 8 Weeks—0/55 (0%)14/55 (25.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlaceboPlacebo (Early Escape)Ustekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 Weeks
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders1/551/160/540/550/540/55
Lobar PneumoniaInfections and infestations0/550/160/540/551/540/55
Urinary Tract InfectionInfections and infestations0/550/161/540/550/540/55
ConcussionInjury, poisoning and procedural complications0/550/161/540/550/540/55
SciaticaNervous system disorders0/550/161/540/550/540/55
ShockVascular disorders0/550/161/540/550/540/55
AnaemiaBlood and lymphatic system disorders0/550/161/540/550/540/55
GastroenteritisInfections and infestations0/550/160/540/551/540/55
Breast Cancer Stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)0/550/160/540/551/540/55
Angina UnstableCardiac disorders1/550/160/540/550/540/55
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboPlacebo (Early Escape)Ustekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 Weeks
NasopharyngitisInfections and infestations3/551/165/544/554/543/55
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders1/550/162/545/554/542/55
HeadacheNervous system disorders3/551/162/545/553/542/55
HypertensionVascular disorders3/551/164/542/551/541/55
BronchitisInfections and infestations1/550/162/542/554/542/55
DyspepsiaGastrointestinal disorders1/551/160/540/550/540/55
AstheniaGeneral disorders0/551/162/541/551/541/55
PharyngitisInfections and infestations0/551/160/541/550/541/55
Urinary Tract InfectionInfections and infestations0/551/160/541/550/540/55
Aspartate Aminotransferase IncreasedInvestigations1/551/160/541/550/541/55

Baseline characteristics

Analysis population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 WeeksTotal
Mean51.1 ± 10.5750.8 ± 13.0151.4 ± 13.5954.6 ± 11.3449.9 ± 12.8551.5 ± 12.34
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 WeeksTotal
Female4846474245228
Male798121046
Region of Enrollment
Region of Enrollment(participants)PlaceboUstekinumab 90 mg Every 8 WeeksUstekinumab 90 mg Every 12 WeeksCNTO1959 200 mg Every 8 WeeksCNTO1959 50 mg Every 8 WeeksTotal
Argentina1565623
Bulgaria222219
CZ Rep001001
Chile111126
Colombia109861043
Hungary6524320
Poland5867935
Russia201518191486
Singapore110204
USA001001
Ukraine991081046
08

Study locations

51 sites
  • Palm Harbor, Florida, United States
  • Rock Island, Illinois, United States
  • Saint Louis, Missouri, United States
  • Buenos Aires, Argentina
  • Ciudad Autónoma De Buenos Aires, Argentina
  • San Juan, Argentina
  • Tucumán, Argentina
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Osorno, Chile
  • Bogota, Colombia
  • Bucaramanga, Colombia
  • Cali, Colombia
  • Chia, Colombia
  • Medellin, Colombia
  • Medellín, Colombia
  • Hlucin, Czech Republic
  • Kladno, Czech Republic
  • Uherske Hradiste, Czech Republic
  • Budapest, Hungary
  • Gödöllő, Hungary
  • Szekesfehervar, Hungary
  • Szombathely, Hungary
  • Veszprém, Hungary
  • Bialystok, Poland
  • Elblag, Poland
  • Krakow, Poland
  • Poznan, Poland
  • Sopot, Poland
  • Sosnowiec, Poland
  • Warszawa, Poland
  • Warszaw, Poland
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Novosibirsk, Russian Federation
  • Petrozavodsk, Russian Federation
  • Saint Petersburg, Russian Federation
  • Saratov, Russian Federation
  • St.-Petersburg, Russian Federation
  • Ufa, Russian Federation
  • Ulyanovsk, Russian Federation
  • Yaroslavl, Russian Federation
  • Singapore, Singapore
  • Donetsk, Ukraine
  • Ivano-Frankovsk, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Simferopol, Ukraine
  • Ternopil, Ukraine
  • Uzhgorod, Ukraine
  • Vinnitsa, Ukraine
09

References and documents

Publications

  • Smolen JS, Agarwal SK, Ilivanova E, Xu XL, Miao Y, Zhuang Y, Nnane I, Radziszewski W, Greenspan A, Beutler A, Baker D. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis. 2017 May;76(5):831-839. doi: 10.1136/annrheumdis-2016-209831. Epub 2017 Jan 13. PubMed 28087506 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Dec 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2012
First posted
Jul 20, 2012
Start
Aug 2012
Primary completionActual
Dec 2013
CompletionActual
May 2014
Results first posted
Dec 19, 2014
Last update
May 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01645280
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Aug 2012
Primary completion
Dec 2013
Completion
May 2014
Results posted
Dec 19, 2014
Last update
May 12, 2016

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ustekinumab · Methotrexate · Guselkumab

Start the discussion